The clinical outcomes are complex and often involve multiple systems. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological evaluations.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnostics and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immunodeficiency disorders that were previously difficult to treat have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely regimens according to changes in conditions.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of malignant epilepsy. The platform serves a team of internationally authoritative experts in the field of self-immunity and rheumatic immunity within the China International Medical Service System, providing the following services to patients: 1. Remote pre-diagnosis: Pre-examination of medical records, clear diagnostic directions and medical advice by a team of experts; 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.